As one of the series of activities of the China Hepatitis C Elimination Alliance Public Welfare Project, the training Session on WHO and national guidelines for hepatitis C prevention and control was held in Ningbo, Zhejiang province on Dec 3, 2019. This session was co-sponsored by China Liver Health and Ningbo Center for Disease Control and Prevention (CDC). More than 120 healthcare workers from CDC and medical institutions in Ningbo, Hangzhou, Quzhou, Zhoushan and surrounding cities and counties participated in the training.
Guests on the rostrum
Participants at the meeting Academician Zhuang Hui (honorary chairman of China Liver Health), Dr. Chen Zhongdan from WHO Representative Office in China, secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC, deputy director Zhang Guoping from the Health Commission of Ningbo, director Xu Guozhang and deputy director Dong Hongjun from Ningbo CDC, director Li Mingyang from China Liver Health, president Cai Ting and vice president Hu Yaoren from Hwa Mei Hospital under University of Chinese Academy of Sciences and other experts attended the training session. Dong Feng, chief of the disease prevention and control division of the Health Commission of Ningbo, and deputy director Shen Yingsheng from China Liver Health presided over the meeting.
Zhang Guoping, deputy director of the Health Commission of Ningbo Zhang Guoping, deputy director of the Health Commission of Ningbo, first extended a warm welcome to academician Zhuang Hui and other experts. He pointed out that Ningbo attached great importance to the prevention and control of hepatitis C. In 2018, three drugs for the treatment of hepatitis C are included in the coverage of critical illness insurance. In 2019, it is determined that outpatient fees for antiviral treatment of hepatitis C will be paid in the mode of payment by type of disease. In November, the Ningbo Action Plan for Eliminating Viral Hepatitis C as a Public Health Threat (2019-2022) is issued. With the recent success of medical insurance access negotiations, the price of hepatitis C treatment drugs has dropped significantly, creating favorable conditions for the action of eliminating hepatitis C.
Academician Zhuang Hui, honorary chairman of China Liver Health Academician Zhuang Hui interpreted the epidemic situation and disease burden of hepatitis in Chinese mainland. He conferred the plaque of Base Hospital of China Hepatitis C Elimination Alliance Public Welfare Project to director Xu Guozhang from Ningbo CDC and president Cai Ting from Hwa Mei Hospital under University of Chinese Academy of Sciences.
Awarding ceremony for Ningbo CDC
Awarding ceremony for Hwa Mei Hospital under University of Chinese Academy of Sciences Secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC and Dr. Chen Zhongdan from WHO representative office in China interpreted the disease burden, prevention and control status of hepatitis C and current challenges in China and worldwide respectively. There are about 7.6 million people infected with hepatitis C virus (HCV) domestically. According to the Global Health Sector Strategy (GHSS) on Viral Hepatitis adopted by the World Health Assembly, China should achieve the goal of 90% of HCV infections being diagnosed and 80% of confirmed cases being treated by 2030. In terms of this goal, healthcare workers in China still have a long way to go.
Secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC
Dr. Chen Zhongdan from WHO representative office in China Vice president Hu Yaoren from Hwa Mei Hospital under University of Chinese Academy of Sciences introduced the guideline on hepatitis C prevention and treatment and the application of Sofosbuvir-based therapy in the treatment of hepatitis C.
Vice president Hu Yaoren from Hwa Mei Hospital under University of Chinese Academy of Sciences
Director Li Mingyang from China Liver Health Director Li Mingyang introduced the China Hepatitis C Elimination Alliance Public Welfare Project. He said that, under the guidance of Health Commission of Ningbo and based on medical insurance policy for hepatitis C treatment, the project would carry out in-depth cooperation with local hospitals, provide supports for primary health care institutions to carry out health education for hepatitis C prevention and control in communities, provide help in the detection and diagnosis of high-risk groups so as to contribute to hepatitis C elimination in Ningbo.
In the afternoon, leaders from Ningbo CDC and others experts further discussed the disease burden of hepatitis C and the strategy for eliminating hepatitis C in Ningbo.
Group photo of experts |
关注官方微信 
